232 related articles for article (PubMed ID: 29032719)
41. Outcomes of Patients With Therapy-Related MDS After Chemoimmunotherapy for Chronic Lymphocytic Leukemia Compared With Patients With De Novo MDS: A Single-Institution Experience.
Cooper JP; Khajaviyan S; Smith SD; Maloney DG; Shustov AR; Warren EH; Soma LA; Lynch RC; Ujjani C; Till B; Halpern AB; Gopal AK; Deeg HJ; Scott BL; Shadman M
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):390-395. PubMed ID: 30948330
[TBL] [Abstract][Full Text] [Related]
42. Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia.
Seymour JF; Kipps TJ; Eichhorst B; Hillmen P; D'Rozario J; Assouline S; Owen C; Gerecitano J; Robak T; De la Serna J; Jaeger U; Cartron G; Montillo M; Humerickhouse R; Punnoose EA; Li Y; Boyer M; Humphrey K; Mobasher M; Kater AP
N Engl J Med; 2018 Mar; 378(12):1107-1120. PubMed ID: 29562156
[TBL] [Abstract][Full Text] [Related]
43. FCR front-line therapy and quality of life in patients with chronic lymphocytic leukemia.
Kutsch N; Busch R; Bahlo J; Mayer J; Hensel M; Hopfinger G; Hess G; von Grünhagen U; Wendtner CM; Maria Fink A; Fischer K; Hallek M; Eichhorst B
Leuk Lymphoma; 2017 Feb; 58(2):399-407. PubMed ID: 27357445
[TBL] [Abstract][Full Text] [Related]
44. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
Robak T; Lech-Maranda E; Robak P
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
[TBL] [Abstract][Full Text] [Related]
45. An observational study of outcomes after initial infused therapy in Medicare patients diagnosed with chronic lymphocytic leukemia.
Danese MD; Griffiths RI; Gleeson M; Satram-Hoang S; Knopf K; Mikhael J; Reyes C
Blood; 2011 Mar; 117(13):3505-13. PubMed ID: 21190994
[TBL] [Abstract][Full Text] [Related]
46. Relapsed chronic lymphocytic leukemia retreated with rituximab: interim results of the PERLE study.
Chaoui D; Choquet S; Sanhes L; Mahé B; Hacini M; Fitoussi O; Arkam Y; Orfeuvre H; Dilhuydy MS; Barry M; Jourdan E; Dreyfus B; Tempescul A; Leprêtre S; Bardet A; Leconte P; Maynadié M; Delmer A
Leuk Lymphoma; 2017 Jun; 58(6):1366-1375. PubMed ID: 28271952
[TBL] [Abstract][Full Text] [Related]
47. Fludarabine, cyclophosphamide, and multiple-dose rituximab as frontline therapy for chronic lymphocytic leukemia.
Short NJ; Keating MJ; Wierda WG; Faderl S; Ferrajoli A; Estrov Z; Smith SC; O'Brien SM
Cancer; 2015 Nov; 121(21):3869-76. PubMed ID: 26218678
[TBL] [Abstract][Full Text] [Related]
48. Outcome of patients aged 80 years or older treated for chronic lymphocytic leukaemia.
Al-Sawaf O; Bahlo J; Robrecht S; Fischer K; Herling CD; Hoechstetter M; Fink AM; von Tresckow J; Langerbeins P; Cramer P; Stilgenbauer S; Wendtner CM; Eichhorst B; Hallek M; Goede V
Br J Haematol; 2018 Dec; 183(5):727-735. PubMed ID: 30460980
[TBL] [Abstract][Full Text] [Related]
49. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia.
Maurer C; Pflug N; Bahlo J; Kluth S; Rhein C; Cramer P; Gross-Ophoff C; Langerbeins P; Fink AM; Eichhorst B; Kreuzer KA; Fischer N; Tausch E; Stilgenbauer S; Böttcher S; Döhner H; Kneba M; Dreyling M; Binder M; Hallek M; Wendtner CM; Bergmann M; Fischer K;
Eur J Haematol; 2016 Sep; 97(3):253-60. PubMed ID: 26643449
[TBL] [Abstract][Full Text] [Related]
50. Assessment of rituximab-abbs, a biosimilar, and rituximab outcomes in patients with CLL or NHL: A real-world UK study.
McBride A; Daniel S; Driessen MT; Szende A; Choudhry A; Tian M; Ariely R; Thompson S
Leuk Res; 2021 Dec; 111():106671. PubMed ID: 34530254
[TBL] [Abstract][Full Text] [Related]
51. A network meta-analysis of progression free survival and overall survival in first-line treatment of chronic lymphocytic leukemia.
Ladyzynski P; Molik M; Foltynski P
Cancer Treat Rev; 2015 Feb; 41(2):77-93. PubMed ID: 25512118
[TBL] [Abstract][Full Text] [Related]
52. Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany.
Kajüter H; Wellmann I; Khil L; Jöckel KH; Zhang C; Fink AM; Hallek M; Stang A
Blood Cancer J; 2021 Oct; 11(10):174. PubMed ID: 34716290
[TBL] [Abstract][Full Text] [Related]
53. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL-8a mabtenance trial.
Egle A; Melchardt T; Obrtlíková P; Smolej L; Kozák T; Steurer M; Andel J; Burgstaller S; Mikušková E; Gercheva L; Nösslinger T; Papajík T; Ladická M; Girschikofsky M; Hrubiško M; Jäger U; Voskova D; Pecherstorfer M; Králiková E; Burcoveanu C; Spasov E; Petzer A; Mihaylov G; Raynov J; Oexle H; Zabernigg A; Flochová E; Palášthy S; Stehlíková O; Doubek M; Altenhofer P; Weiss L; Magnes T; Pleyer L; Klingler A; Mayer J; Greil R
Cancer Med; 2019 Apr; 8(4):1401-1405. PubMed ID: 30888118
[TBL] [Abstract][Full Text] [Related]
54. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.
Appleby N; O'Brien D; Quinn FM; Smyth L; Kelly J; Parker I; Scott K; Cahill MR; Crotty G; Enright H; Hennessy B; Hodgson A; Leahy M; O'Leary H; O'Dwyer M; Hayat A; Vandenberghe EA
Leuk Lymphoma; 2018 Jun; 59(6):1338-1347. PubMed ID: 28925785
[TBL] [Abstract][Full Text] [Related]
55. miR-125b and miR-532-3p predict the efficiency of rituximab-mediated lymphodepletion in chronic lymphocytic leukemia patients. A French Innovative Leukemia Organization study.
Gagez AL; Duroux-Richard I; Leprêtre S; Orsini-Piocelle F; Letestu R; De Guibert S; Tuaillon E; Leblond V; Khalifa O; Gouilleux-Gruart V; Banos A; Tournilhac O; Dupuis J; Jorgensen C; Cartron G; Apparailly F
Haematologica; 2017 Apr; 102(4):746-754. PubMed ID: 28126961
[TBL] [Abstract][Full Text] [Related]
56. The Connect CLL Registry: final analysis of 1494 patients with chronic lymphocytic leukemia across 199 US sites.
Mato A; Nabhan C; Lamanna N; Kay NE; Grinblatt DL; Flowers CR; Farber CM; Davids MS; Swern AS; Sullivan K; Flick ED; Gressett Ussery SM; Gharibo M; Kiselev P; Sharman JP
Blood Adv; 2020 Apr; 4(7):1407-1418. PubMed ID: 32271900
[TBL] [Abstract][Full Text] [Related]
57. Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.
Bachow SH; Lamanna N
Curr Hematol Malig Rep; 2016 Feb; 11(1):61-70. PubMed ID: 26951237
[TBL] [Abstract][Full Text] [Related]
58. A phase I dose-ranging study of bendamustine and rituximab in chronic lymphocytic leukemia patients with comorbidities.
Danilov AV; Lewis LD; Lansigan F; Roudaia L; Findley DL; Jones SY; Highhouse B; Beaulieu BB; Brown JR
Br J Haematol; 2017 Sep; 178(5):820-823. PubMed ID: 27377970
[No Abstract] [Full Text] [Related]
59. Effectiveness of the Combination of Rituximab and Standard Chemotherapeutic Regimens in Previously Untreated Patients with Chronic Lymphocytic Leukaemia in Real-Life: Results from a Noninterventional Study (CILI Study).
Szász R; Altai E; Pál K; Dombi P; Iványi J; Jakucs J; Jóni N; Illés Á; Tárkányi I; Szerafin L; Nagy Z; Farkas P; Nagy Á; Piukovics K; Ujj G; Schneider T
Pathol Oncol Res; 2019 Apr; 25(2):535-540. PubMed ID: 30361908
[TBL] [Abstract][Full Text] [Related]
60. Bendamustine in combination with rituximab for elderly patients with previously untreated B-cell chronic lymphocytic leukemia: A retrospective analysis of real-life practice in Italian hematology departments.
Laurenti L; Innocenti I; Autore F; Vannata B; Efremov DG; Ciolli S; Del Poeta G; Mauro FR; Cortelezzi A; Borza PA; Ghio F; Mondello P; Murru R; Gozzetti A; Cariccio MR; Piccirillo N; Boncompagni R; Cantonetti M; Principe MI; Reda G; Bongarzoni V; Cervetti G; Pitini V; Foà R; Sica S; D'Arena G
Leuk Res; 2015 Oct; 39(10):1066-70. PubMed ID: 26307523
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
